Multiple Myeloma Response Criteria (IMWG)

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۱۰۰ • واحد: %

حداقل ۰.۰۱ — حداکثر ۱۰۰۰

حداقل ۰ — حداکثر ۱۰۰ • واحد: %

حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: mg

حداقل ۰ — حداکثر ۱۰۰ • واحد: %

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
response category
—امتیاز
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Stringent Complete Response (sCR)1–1
  • Complete Response (CR)2–2
  • Very Good Partial Response (VGPR)3–3
  • Partial Response (PR)4–4
Direct Clinical Answer

The Multiple Myeloma Response Criteria (IMWG) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include serum immunofixation. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Evaluates disease response in multiple myeloma according to International Myeloma Working Group (IMWG) criteria including Complete Response, Partial Response, and Progressive Disease categories.

Clinical Indication

The Multiple Myeloma Response Criteria (IMWG) is indicated for bedside clinical practice to support Evaluates disease response in multiple myeloma according to International Myeloma Working Group (IMWG) criteria including Complete Response, Partial Response, and Progressive Disease categories.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Integration with survival outcomes guides treatment decisions.

Formula & Variables:

IMWG Response Assessment: Based on immunofixation results, bone marrow plasma cell percentage, M protein levels, soft tissue plasmacytomas, free light chain ratio, and clonal cell presence to determine response category (sCR, CR, VGPR, PR, SD, or PD)

Input Parameters

NameTypeRequiredDescription
serum_immunofixationstringYesSerum immunofixation result
urine_immunofixationstringYesUrine immunofixation result
bone_marrow_plasma_cellsfloatYesPercentage of plasma cells in bone marrow(%)
soft_tissue_plasmacytomasstringYesPresence of soft tissue plasmacytomas
free_light_chain_ratiofloatNoSerum free light chain ratio (involved/uninvolved)
clonal_cells_bone_marrowstringNoClonal cells in bone marrow by immunohistochemistry/immunofluorescence
serum_m_protein_reductionfloatNoPercentage reduction in serum M protein from baseline(%)
urine_m_protein_24hfloatNo24-hour urine M protein level(mg)
serum_electrophoresis_detectablestringNoM component detectable by serum electrophoresis
plasmacytoma_reductionfloatNoPercentage reduction in soft tissue plasmacytoma size(%)

Score Interpretation & Guidance

RangeStageDescription
1–1Stringent Complete Response (sCR)Best possible response
2–2Complete Response (CR)Complete response
3–3Very Good Partial Response (VGPR)Very good partial response
4–4Partial Response (PR)Partial response
5–5Stable Disease (SD)Stable disease
6–6Progressive Disease (PD)Disease progression

Evidence-Based References (EBM)

  • Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.DOI: 10.1016/S1470-2045(16)30206-6
  • Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-73. doi: 10.1038/sj.leu.2404284.DOI: 10.1038/sj.leu.2404284
  • Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus guidelines for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-5. doi: 10.1182/blood-2010-10-299487.DOI: 10.1182/blood-2010-10-299487

Related calculators